Graft-versus-host reactions and bone-marrow transplantation

Curr Opin Immunol. 1991 Oct;3(5):752-7. doi: 10.1016/0952-7915(91)90108-d.


Three areas of bone-marrow transplantation have developed particularly rapidly during the past year. First, increasing numbers of bone-marrow transplants using matched unrelated donors or HLA-mismatched family members have been successfully performed. Second, trials of recombinant hemopoietic growth factors have shown these agents can accelerate hemopoietic recovery after bone-marrow transplant and reduce the incidence of infections and other post-transplant complications. But potentially the most important advances have come in a series of separate observations, which in conjunction suggest mechanisms by which the anti-leukemic activity of an allograft may be separated from its ability to induce graft-versus-host disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antigens, Differentiation, T-Lymphocyte / immunology
  • Bone Marrow Transplantation / immunology*
  • CD3 Complex
  • Graft vs Host Reaction*
  • Hematopoiesis / drug effects
  • Hematopoietic Cell Growth Factors / therapeutic use
  • Histocompatibility
  • Humans
  • Killer Cells, Natural / immunology
  • Leukemia / immunology
  • Leukemia / surgery
  • Lymphocyte Activation
  • Mice
  • Mice, Inbred C57BL
  • Radiation Chimera
  • Receptors, Antigen, T-Cell / immunology
  • Recombinant Proteins / therapeutic use


  • Antigens, Differentiation, T-Lymphocyte
  • CD3 Complex
  • Hematopoietic Cell Growth Factors
  • Receptors, Antigen, T-Cell
  • Recombinant Proteins